Welcome to our dedicated page for Vaccinex news (Ticker: VCNX), a resource for investors and traders seeking the latest updates and insights on Vaccinex stock.
Vaccinex, Inc. (VCNX) is a clinical-stage biotechnology company headquartered in Rochester, NY. Specializing in the discovery and development of human therapeutic monoclonal antibodies, therapeutic vaccines, and other biologic products, Vaccinex is dedicated to addressing serious diseases with unmet medical needs, including cancer, multiple sclerosis, and other autoimmune diseases.
The company is pioneering a unique approach to treating cancer and neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). Vaccinex's leading drug candidate, pepinemab, is designed to block SEMA4D, a potent agent believed to prevent immune infiltration into tumors and reduce inflammation in chronic brain diseases. Currently, pepinemab is undergoing evaluation in a Phase 1b/2 study for recurrent or metastatic head and neck cancer and in a Phase 1/2a study for Alzheimer’s Disease. Additionally, there is ongoing exploration for potential Phase 3 development in Huntington's disease.
Vaccinex conducts research both in-house and through collaborations with prominent academic institutions and biotechnology firms. The company's proprietary drug discovery platform, ActivMAb, plays a significant role in its innovative drug development approach. The development team at Vaccinex comprises experienced industry veterans skilled in therapeutic biologics research, manufacturing, quality control, toxicology, pharmacology, regulatory affairs, and clinical affairs.
Recently, Vaccinex has achieved notable milestones, including a 1-for-15 reverse stock split to regain compliance with Nasdaq listing standards and the advancement of its clinical trials. The company continues to secure funding for its research, with significant investments from the Alzheimer’s Drug Discovery Foundation and grants from the Alzheimer’s Association.
Vaccinex remains committed to advancing its clinical programs and expanding its pipeline of innovative therapies to improve patient outcomes in challenging diseases.
Vaccinex, Inc. (Nasdaq: VCNX) announced its selection for a poster presentation at the 2022 Alzheimer’s Association International Conference, scheduled from July 31 to August 4 in San Diego. The presentation will focus on pepinemab, its innovative treatment for Alzheimer’s Disease, which targets SEMA4D. The ongoing Phase 1/2a SIGNAL-AD study aims to evaluate the safety and effects of pepinemab in early-stage Alzheimer’s patients. The study is partially funded by the Alzheimer’s Drug Discovery Foundation and the Alzheimer’s Association.
Vaccinex, Inc. (Nasdaq: VCNX) announced that Dr. Maurice Zauderer and Dr. Elizabeth Evans will present at the Jefferies Healthcare Conference on June 10, 2022, at 10:30 a.m. ET. They will update investors on progress in phase 2 trials for their lead product, pepinemab, targeting head and neck cancer and Alzheimer’s disease. One-on-one meetings will occur from June 8 to 10. Pepinemab aims to inhibit SEMA4D to prevent immune infiltration in tumors and inflammation in chronic brain diseases, with ongoing studies for Huntington’s disease development.
Vaccinex, Inc. (Nasdaq: VCNX) announced promising results from its clinical trial of pepinemab in combination with KEYTRUDA for treating recurrent/metastatic head and neck cancer, noting two complete responses among the first three patients. The Phase 1b/2 KEYNOTE-B84 trial has 65 planned participants. Additionally, enrollment is ongoing for the SIGNAL-AD trial in early Alzheimer’s disease. Financially, Vaccinex reported cash equivalents of $16.8 million as of March 31, 2022, with a net loss of $4.6 million for the quarter, an improvement from $6.6 million the previous year.
Vaccinex, Inc. (Nasdaq: VCNX), a biotechnology firm focused on cancer and neurodegenerative disease therapies, announced its selection for a poster presentation at the 18th Annual PEGS Boston Conference from May 2-6, 2022. The presentation will showcase their ActivMAb technology, which enables efficient expression of complex transmembrane receptors critical for drug discovery. This groundbreaking platform successfully identifies antibodies against targets like SARS-CoV2 and chemokine receptor CXCR4. Details will be accessible on their website starting May 2 at 3:50 PM EST.
Vaccinex, Inc. (Nasdaq: VCNX) reported positive developments in its ongoing clinical trials for pepinemab in oncology and neurodegenerative diseases. The Phase 1b segment of the KEYNOTE-B84 study in head and neck cancer showed two complete responses among three initial patients. Enrollment is ongoing for both the KEYNOTE-B84 and SIGNAL-AD trials, with topline data expected in 2023. Financially, Vaccinex ended 2021 with $8.6 million in cash, reflecting a decrease from $10.6 million in 2020. The comprehensive loss for 2021 was $22.4 million, an improvement from $28.9 million in the previous year.
Vaccinex, Inc. (Nasdaq: VCNX) announced its selection for a poster presentation at the 2022 American Association for Cancer Research Meetings, showcasing the phase 1b segment of the KEYNOTE-B84 study. This study evaluates pepinemab in combination with KEYTRUDA for patients with recurrent or metastatic head and neck cancer. The presentation is scheduled for April 11, 2022, featuring abstract CT111 by VP Clinical Science Terrence Fisher. Vaccinex holds global rights to pepinemab, which aims to improve tumor immunity and shows promise in ongoing clinical trials.
Vaccinex, Inc. (Nasdaq: VCNX) announced a poster presentation for its research on combination immunotherapy and HTT-lowering in humanized HD mice at the 17th Annual HD Therapeutics Conference on March 2, 2022. The presentation, led by Dr. Amber Southwell, will explore the efficacy of pepinemab in treating Huntington's disease by inhibiting semaphorin 4D (SEMA4D). The conference serves as a platform for advancing research in neurodegenerative diseases. Detailed presentation information and links are available on the company’s website.
Vaccinex announces a stock purchase agreement on January 27, 2022, with existing and new investors for a private placement of 5,945,943 shares at $1.11 per share, yielding approximately $6.6 million. This funding is part of a total of $10.1 million in new equity financing for January 2022. The proceeds will support the development of pepinemab, its lead drug candidate for cancer and neurodegenerative diseases. The placement is expected to close by January 31, 2022, and includes a registration rights agreement with investors.
Vaccinex, a clinical-stage biotechnology firm, announced positive interim results from the Phase Ib segment of the KEYNOTE-B84 study, featuring its drug pepinemab combined with Merck's KEYTRUDA for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Of three patients, two achieved a complete response (CR), despite low PD-L1 biomarker levels. The recommended dose of pepinemab was well tolerated, allowing the continuation of treatment.
Vaccinex plans to expand the trial, enrolling up to an additional 62 patients, and aims to share further findings at a medical conference in 2022.
Vaccinex, Inc. (Nasdaq: VCNX) announced positive interim safety data from the Phase 1b segment of the KEYNOTE B84 study, evaluating the combination of pepinemab and Keytruda in advanced head and neck cancer patients. The safety run-in phase confirmed that pepinemab (20 mg/kg) and Keytruda (200 mg Q3W) were well tolerated, paving the way for the Phase 2 expansion segment, which will enroll up to 62 subjects. This study aims to assess the Objective Response Rate (ORR) and other key metrics, with interim results expected in the second half of 2022.
FAQ
What is the current stock price of Vaccinex (VCNX)?
What is the market cap of Vaccinex (VCNX)?
What is Vaccinex, Inc.?
Where is Vaccinex, Inc. located?
What is Vaccinex's lead drug candidate?
What is the focus of Vaccinex's research?
What clinical studies is pepinemab involved in?
What is the ActivMAb platform?
Who are Vaccinex's research partners?
What recent milestone has Vaccinex achieved?
How is Vaccinex funded?
Who leads the development team at Vaccinex?
